欧洲白血病网2020年慢性髓性白血病治疗建议
欧洲白血病网召集专家小组更新慢性髓性白血病(CML)治疗建议。慢性期患者一线可用伊马替尼原研或仿制、达沙替尼、尼洛替尼和博舒替尼,仿制伊马替尼具成本效益。诊断时用ELTS评分评估风险,尽可能用定量PCR监测反应,3个月BCR-ABL1>10%确认提示治疗失败,持续深度分子学缓解者可考虑停药追求无治疗缓解。
要点
- 慢性期一线可选伊马替尼(原研或仿制)、达沙替尼、尼洛替尼或博舒替尼。
- 诊断时采用ELTS评分评估风险,尽可能用定量PCR监测分子学反应。
- 3个月BCR-ABL1>10%确认提示治疗失败,持续深度分子学缓解可考虑停药。
核心结论
- 慢性期CML患者多数已可达正常预期寿命,另一目标是获得稳定深度分子学缓解并停药实现无治疗缓解。
研究设计与样本
- 欧洲白血病网召集专家小组对既往建议以来的证据进行批判性评估和更新。
主要发现
- 过去7年CML治疗格局已发生深刻变化,多数慢性期患者预期寿命正常。
- 仿制伊马替尼是慢性期具成本效益的初始治疗。
- 3个月时BCR-ABL1>10%经确认提示治疗失败。
- 持续深度分子学缓解者可考虑停药以实现无治疗缓解。
关键数值与推荐
- 一线可用TKI包括伊马替尼原研或仿制、达沙替尼、尼洛替尼和博舒替尼。
- 诊断时应用新的EUTOS长期生存(ELTS)评分评估患者风险状态。
- 尽可能用定量聚合酶链反应监测反应。
- 不能缓解的不耐受或未达分子学里程碑时建议更换治疗。
- 3个月BCR-ABL1>10%经确认提示治疗失败。
临床怎么用
- 慢性期初始治疗可优先考虑具成本效益的仿制伊马替尼,并考虑各TKI禁忌症和副作用。
- 用ELTS评分进行诊断时风险分层,用定量PCR动态监测分子学反应。
- 出现不可缓解的不耐受或未达分子学里程碑时更换治疗,持续深度分子学缓解者可考虑停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
引用
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020. PMID: 32127639. doi:10.1038/s41375-020-0776-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。